The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and hepatotoxicity of Infliximab in resolving steroid-refractory immune-related adverse events (irAEs) in a real-world setting.
 
Thiago Pimentel Muniz
No Relationships to Disclose
 
Daniel Vilarim Araujo
Honoraria - BMS Brazil; GlaxoSmithKline; Libbs
 
Anjie Yang
No Relationships to Disclose
 
Hadas Sorotsky
No Relationships to Disclose
 
Sareh Keshavarzi
No Relationships to Disclose
 
Marcus O. Butler
Honoraria - Bristol-Myers Squibb; Merck; Novartis; Roche
Consulting or Advisory Role - Adaptimmune; Bristol-Myers Squibb; EMD Serono; Genzyme; GlaxoSmithKline; GlaxoSmithKline; Immunocore; Immunovaccine; LaRoche Posay; Merck; Novartis; Sanofi
Research Funding - Merck; Takara Bio
Expert Testimony - Merck
 
Samuel Saibil
Consulting or Advisory Role - Janssen
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
Anna Spreafico
Honoraria - Janssen Oncology
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis; Oncorus
Research Funding - Alkermes; Array BioPharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Janssen Oncology; Merck; Northern Biologics; Novartis; Replimune; Roche; Surface Oncology; Symphogen
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Idera; Janssen Oncology; Merck; Roche
 
David Hogg
Consulting or Advisory Role - BMSi; Merck; Merck Serono; Novartis; Roche
Research Funding - BMSi; Merck Serono